StemRIM StemRIM

Investor Library

StemRIMIR LibraryTimely Disclosure Information
All Timely Disclosure Information Financial Results Presentation Materials IR News
October 7, 2026 Timely Disclosure Information
Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
September 25, 2026 Timely Disclosure Information
Patent Registration in South Korea for Redasemtide in Cartilage Disorders
September 25, 2026 Timely Disclosure Information
Nomination of Director Candidates, Audit & Supervisory Board Member and Substitute Audit & Supervisory Board Member Candidates
September 25, 2026 Timely Disclosure Information
Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
September 10, 2026 Timely Disclosure Information
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
September 10, 2026 Timely Disclosure Information
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
September 9, 2026 Timely Disclosure Information
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
September 9, 2026 Timely Disclosure Information
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
September 9, 2026 Timely Disclosure Information
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2026 [Japanese GAAP]
August 3, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
July 22, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
July 13, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
July 8, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (SR-GT1) Aimed at Curative Treatment of DEB in ,South Korea
June 17, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
June 16, 2026 Timely Disclosure Information
StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis